Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition
NCT ID: NCT07332338
Last Updated: 2026-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TEMPORARILY_NOT_AVAILABLE
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition
NCT07184385
Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome
NCT05682560
Safety and Efficacy of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in the Treatment of Long-Term Cytopenia After CAR-T Therapy
NCT07212335
Ubiquinol as a Metabolic Resuscitator in Post-Cardiac Arrest
NCT02934555
Stem Cell Study for Long COVID-19 Neurological Symptoms
NCT06156241
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
REGENECYTE®
HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* With post-COVID condition
* Has had a recent (within 7 days) negative SARS-CoV-2 test (an approved PCR (polyermerase chain reaction) or antigen test)
* Not eligible for participation in any ongoing clinical trials of post-COVID condition with REGENECYTE
* Able to provide signed informed consent (by the subject or his/her legally authorized representative)
* Is willing and able to participate in all aspects of the study, including completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing a written informed consent
Exclusion Criteria
* With pre-existing terminal illness
* With known immune disease
* Is pregnant or breastfeeding
* Is currently participating in another investigational study or has been taking any other investigational product (IP) within the last 4 weeks before screening
* Has received any vaccination within 3 weeks prior to the first IP infusion or planning to receive vaccination during the treatment period
* Judged by the investigator to be not suitable for study participation, including but not limited to pre-existing chronic diseases
* Under the conditions that may increase risk of complications based on the medical judgment of the investigator and the parameters
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
StemCyte, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SCUS001-EA1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.